{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T06:11:14Z","timestamp":1775974274429,"version":"3.50.1"},"reference-count":97,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T00:00:00Z","timestamp":1741305600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T00:00:00Z","timestamp":1741305600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22K15531"],"award-info":[{"award-number":["22K15531"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s11060-025-04995-1","type":"journal-article","created":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T17:03:35Z","timestamp":1741367015000},"page":"263-273","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Gene therapy and genome-editing for schwannoma in NF2-related schwannomatosis: current understanding and future directions"],"prefix":"10.1007","volume":"173","author":[{"given":"Ryota","family":"Tamura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Yo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Toda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,7]]},"reference":[{"key":"4995_CR1","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1016\/S0140-6736(09)60259-2","volume":"373","author":"AR Asthagiri","year":"2009","unstructured":"Asthagiri AR, Parry DM, Butman JA, Kim HJ, Tsilou ET, Zhuang Z, Lonser RR (2009) Neurofibromatosis type 2. Lancet 373:1974\u20131986","journal-title":"Lancet"},{"key":"4995_CR2","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1750-1172-4-16","volume":"4","author":"DG Evans","year":"2009","unstructured":"Evans DG (2009) Neurofibromatosis type 2 (NF2): a clinical and molecular review. Orphanet J Rare Dis 4:16","journal-title":"Orphanet J Rare Dis"},{"key":"4995_CR3","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1097\/GIM.0b013e3181ac9a27","volume":"11","author":"DG Evans","year":"2009","unstructured":"Evans DG (2009) Neurofibromatosis 2 [Bilateral acoustic neurofibromatosis, central neurofibromatosis, NF2, neurofibromatosis type II]. Genet Med 11:599\u2013610","journal-title":"Genet Med"},{"key":"4995_CR4","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1038\/onc.2008.427","volume":"28","author":"D Lallemand","year":"2009","unstructured":"Lallemand D, Manent J, Couvelard A, Watilliaux A, Siena M, Chareyre F, Lampin A, Niwa-Kawakita M, Kalamarides M, Giovannini M (2009) Merlin regulates transmembrane receptor accumulation and signaling at the plasma membrane in primary mouse Schwann cells and in human schwannomas. Oncogene 28:854\u2013865","journal-title":"Oncogene"},{"key":"4995_CR5","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1056\/NEJM198803173181106","volume":"318","author":"RL Martuza","year":"1988","unstructured":"Martuza RL, Eldridge R (1988) Neurofibromatosis 2 (bilateral acoustic neurofibromatosis). N Engl J Med 318:684\u2013688","journal-title":"N Engl J Med"},{"key":"4995_CR6","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1016\/j.gim.2022.05.007","volume":"24","author":"SR Plotkin","year":"2022","unstructured":"Plotkin SR, Messiaen L, Legius E, Pancza P, Avery RA, Blakeley JO, Babovic-Vuksanovic D, Ferner R, Fisher MJ, Friedman JM, Giovannini M, Gutmann DH, Hanemann CO, Kalamarides M, Kehrer-Sawatzki H, Korf BR, Mautner VF, MacCollin M, Papi L, Rauen KA, Riccardi V, Schorry E, Smith MJ, Stemmer-Rachamimov A, Stevenson DA, Ullrich NJ, Viskochil D, Wimmer K, Yohay K, International Consensus Group on Neurofibromatosis Diagnostic Criteria (I-NF-DC), Huson SM, Wolkenstein P, Evans DG (2022) Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: an international consensus recommendation. Genet Med 24:1967\u20131977","journal-title":"Genet Med"},{"key":"4995_CR7","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.3171\/2016.12.JNS161530","volume":"128","author":"CW Huang","year":"2018","unstructured":"Huang CW, Tu HT, Chuang CY, Chang CS, Chou HH, Lee MT, Huang CF (2018) Gamma Knife radiosurgery for large vestibular schwannomas greater than 3 cm in diameter. J Neurosurg 128:1380\u20131387","journal-title":"J Neurosurg"},{"key":"4995_CR8","doi-asserted-by":"publisher","first-page":"835","DOI":"10.3390\/cancers12040835","volume":"12","author":"L Yao","year":"2020","unstructured":"Yao L, Alahmari M, Temel Y, Hovinga K (2020) Therapy of sporadic and NF2-related vestibular schwannoma. Cancers (Basel) 12:835","journal-title":"Cancers (Basel)"},{"issue":"1","key":"4995_CR9","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1080\/02688690500081206","volume":"19","author":"DG Evans","year":"2005","unstructured":"Evans DG, Baser ME, O\u2019Reilly B, Rowe J, Gleeson M, Saeed S, King A, Huson SM, Kerr R, Thomas N, Irving R, MacFarlane R, Ferner R, McLeod R, Moffat D, Ramsden R (2005) Management of the patient and family with neurofibromatosis 2: a consensus conference statement. Br J Neurosurg 19(1):5\u201312","journal-title":"Br J Neurosurg"},{"key":"4995_CR10","doi-asserted-by":"publisher","DOI":"10.1097\/MAO.0000000000004442","author":"RJT Fujiwara","year":"2025","unstructured":"Fujiwara RJT, Shi JJ, Tan D, Sakano H, Kutz JW (2025) Increased costs and complication rates in vestibular schwannoma resections for neurofibromatosis type 2. Otol Neurotol. https:\/\/doi.org\/10.1097\/MAO.0000000000004442","journal-title":"Otol Neurotol"},{"key":"4995_CR11","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s11701-007-0036-8","volume":"1","author":"S McClelland 3rd","year":"2007","unstructured":"McClelland S 3rd, Gerbi BJ, Cho KH, Hall WA (2007) The treatment of a large acoustic tumor with fractionated stereotactic radiotherapy. J Robot Surg 1:227\u2013230","journal-title":"J Robot Surg"},{"key":"4995_CR12","doi-asserted-by":"crossref","unstructured":"Evans DG, Halliday D, Obholzer R, Afridi S, Forde C, Rutherford SA, Hammerbeck-Ward C, Lloyd SK, Freeman SM, Pathmanaban ON, Thomas OM, Laitt RD, Stivaros S, Kilday JP, Vassallo G, McBain C, Lavin T, Paterson C, Whitfield G, McCabe MG, Axon PR, Halliday J, Mackeith S, Parry A; English Specialist NF2 Research Group; Harkness EF, Buttimore J, King AT (2023) Radiation treatment of benign tumors in NF2-related-schwannomatosis: A national study of 266 irradiated patients showing a significant increase in malignancy\/malignant progression. Neurooncol Adv 5:vdad025.","DOI":"10.1093\/noajnl\/vdad025"},{"issue":"Suppl","key":"4995_CR13","doi-asserted-by":"publisher","first-page":"160","DOI":"10.3171\/2014.7.GKS141311","volume":"121","author":"C Seferis","year":"2014","unstructured":"Seferis C, Torrens M, Paraskevopoulou C, Psichidis G (2014) Malignant transformation in vestibular schwannoma: report of a single case, literature search, and debate. J Neurosurg 121(Suppl):160\u2013166","journal-title":"J Neurosurg"},{"key":"4995_CR14","doi-asserted-by":"publisher","first-page":"3446","DOI":"10.1200\/JCO.19.01367","volume":"37","author":"SR Plotkin","year":"2019","unstructured":"Plotkin SR, Duda DG, Muzikansky A, Allen J, Blakeley J, Rosser T, Campian JL, Clapp DW, Fisher MJ, Tonsgard J, Ullrich N, Thomas C, Cutter G, Korf B, Packer R, Karajannis MA (2019) Multicenter, prospective, phase ii and biomarker study of high-dose bevacizumab as induction therapy in patients with neurofibromatosis type 2 and progressive vestibular schwannoma. J Clin Oncol 37:3446\u20133454","journal-title":"J Clin Oncol"},{"key":"4995_CR15","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1093\/annonc\/mdq566","volume":"21","author":"VF Mautner","year":"2010","unstructured":"Mautner VF, Nguyen R, Knecht R, Bokemeyer C (2010) Radiographic regression of vestibular schwannomas induced by bevacizumab treatment: sustain under continuous drug application and rebound after drug discontinuation. Ann Oncol 21:2294\u20132295","journal-title":"Ann Oncol"},{"key":"4995_CR16","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s11060-016-2276-9","volume":"131","author":"KA Morris","year":"2017","unstructured":"Morris KA, Golding JF, Blesing C, Evans DG, Ferner RE, Foweraker K, Halliday D, Jena R, McBain C, McCabe MG, Swampillai A, Warner N, Wilson S, Parry A, Afridi SK (2017) Toxicity profile of bevacizumab in the UK Neurofibromatosis type 2 cohort. J Neurooncol 131:117\u2013124","journal-title":"J Neurooncol"},{"key":"4995_CR17","doi-asserted-by":"crossref","unstructured":"Webb MJ, Neth BJ, Webb LM, Van Gompel JJ, Link MJ, Neff BA, Carlson ML, Driscoll CL, Dornhoffer J, Ruff MW, Anderson KA, Kizilbash SH, Campian JL, Uhm JH, Lane JI, Benson JC, Blezek DJ, Mehta PM, Bathla G, Sener UT (2023) Withdrawal of bevacizumab is associated with rebound growth of vestibular schwannomas in neurofibromatosis type 2-related schwannomatosis patients. Neurooncol Adv 5:vdad123.","DOI":"10.1093\/noajnl\/vdad123"},{"key":"4995_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28228","volume":"67","author":"S Renzi","year":"2020","unstructured":"Renzi S, Michaeli O, Salvador H, Alderete D, Ponce NF, Zapotocky M, Hansford JR, Malalasekera VS, Toledano H, Maguire B, Bouffet E, Ramaswamy V, Baroni LV (2020) Bevacizumab for NF2-associated vestibular schwannomas of childhood and adolescence. Pediatr Blood Cancer 67:e28228","journal-title":"Pediatr Blood Cancer"},{"issue":"10","key":"4995_CR19","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1007\/s00381-020-04728-x","volume":"36","author":"I Gugel","year":"2020","unstructured":"Gugel I, Zipfel J, Hartjen P, Kluwe L, Tatagiba M, Mautner VF, Schuhmann MU (2020) Managing NF2-associated vestibular schwannomas in children and young adults: review of an institutional series regarding effects of surgery and bevacizumab on growth rates, tumor volume, and hearing quality. Childs Nerv Syst 36(10):2471\u20132480","journal-title":"Childs Nerv Syst"},{"key":"4995_CR20","doi-asserted-by":"crossref","unstructured":"Tamura R, Fujioka M, Morimoto Y, Ohara K, Kosugi K, Oishi Y, Sato M, Ueda R, Fujiwara H, Hikichi T, Noji S, Oishi N, Ogawa K, Kawakami Y, Ohira T, Yoshida K, Toda M (2019) A VEGF receptor vaccine demonstrates preliminary efficacy in neurofibromatosis type 2. Nat Commun 10(1):5758.","DOI":"10.1038\/s41467-019-13640-1"},{"issue":"21","key":"4995_CR21","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1200\/JCO.23.02376","volume":"42","author":"R Tamura","year":"2024","unstructured":"Tamura R, Yamanobe Y, Fujioka M, Morimoto Y, Fukumura M, Nakaya M, Oishi Y, Sato M, Ueda R, Fujiwara H, Hikichi T, Noji S, Oishi N, Ozawa H, Ogawa K, Kawakami Y, Ohira T, Yoshida K, Toda M (2024) Phase I\/II study of a vascular endothelial growth factor receptor vaccine in patients with NF2-related schwannomatosis. J Clin Oncol 42(21):2578\u20132587","journal-title":"J Clin Oncol"},{"key":"4995_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/biotech13010001","volume":"13","author":"ML Henderson","year":"2024","unstructured":"Henderson ML, Zieba JK, Li X, Campbell DB, Williams MR, Vogt DL, Bupp CP, Edgerly YM, Rajasekaran S, Hartog NL, Prokop JW, Krueger JM (2024) Gene therapy for genetic syndromes: understanding the current state to guide future care. BioTech (Basel) 13:1","journal-title":"BioTech (Basel)"},{"key":"4995_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2022.120375","volume":"294","author":"N Sayed","year":"2022","unstructured":"Sayed N, Allawadhi P, Khurana A, Singh V, Navik U, Pasumarthi SK, Khurana I, Banothu AK, Weiskirchen R, Bharani KK (2022) Gene therapy: comprehensive overview and therapeutic applications. Life Sci 294:120375","journal-title":"Life Sci"},{"key":"4995_CR24","doi-asserted-by":"crossref","unstructured":"Volodina O, Smirnikhina S (2024) The future of gene therapy: a review of in vivo and ex vivo delivery methods for genome editing-based therapies. Mol Biotechnol, 16.","DOI":"10.1007\/s12033-024-01070-4"},{"issue":"1","key":"4995_CR25","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1177\/17407745231207970","volume":"21","author":"V Staedtke","year":"2024","unstructured":"Staedtke V, Anstett K, Bedwell D, Giovannini M, Keeling K, Kesterson R, Kim Y, Korf B, Leier A, McManus ML, Sarnoff H, Vitte J, Walker JA, Plotkin SR, Wallis D (2024) Gene-targeted therapy for neurofibromatosis and schwannomatosis: the path to clinical trials. Clin Trials 21(1):51\u201366","journal-title":"Clin Trials"},{"key":"4995_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.omtn.2025.102475","volume":"36","author":"AK O\u2019Donohue","year":"2025","unstructured":"O\u2019Donohue AK, Ginn SL, Burgio G, Berman Y, Dabscheck G, Schindeler A (2025) The evolving landscape of NF gene therapy: hurdles and opportunities. Mol Ther Nucleic Acids 36:1\u201311","journal-title":"Mol Ther Nucleic Acids"},{"key":"4995_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2021.603195","volume":"12","author":"ZY Zhang","year":"2021","unstructured":"Zhang ZY, Wu YY, Cai XY, Fang WL, Xiao FL (2021) Molecular diagnosis of neurofibromatosis by multigene panel testing. Front Genet 12:603195","journal-title":"Front Genet"},{"key":"4995_CR28","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1136\/jmedgenet-2020-106973","volume":"58","author":"Y Teranishi","year":"2021","unstructured":"Teranishi Y, Miyawaki S, Hongo H, Dofuku S, Okano A, Takayanagi S, Ota T, Yoshimura J, Qu W, Mitsui J, Nakatomi H, Morishita S, Tsuji S, Saito N (2021) Targeted deep sequencing of DNA from multiple tissue types improves the diagnostic rate and reveals a highly diverse phenotype of mosaic neurofibromatosis type 2. J Med Genet 58:701\u2013711","journal-title":"J Med Genet"},{"key":"4995_CR29","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.devcel.2010.10.008","volume":"19","author":"AB Gladden","year":"2010","unstructured":"Gladden AB, Hebert AM, Schneeberger EE, McClatchey AI (2010) The NF2 tumor suppressor, Merlin, regulates epidermal development through the establishment of a junctional polarity complex. Dev Cell 19:727\u2013739","journal-title":"Dev Cell"},{"key":"4995_CR30","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s12253-013-9644-y","volume":"19","author":"N Pe\u2019cina-\u0160laus","year":"2013","unstructured":"Pe\u2019cina-\u0160laus N. (2013) Merlin, the NF2 gene product. Pathol Oncol Res 19:365\u2013373","journal-title":"Pathol Oncol Res"},{"key":"4995_CR31","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1517\/14728222.2011.645805","volume":"16","author":"L Santarpia","year":"2012","unstructured":"Santarpia L, Lippman SM, El-Naggar AK (2012) Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert Opin Ther Targets 16:103\u2013119","journal-title":"Expert Opin Ther Targets"},{"issue":"1","key":"4995_CR32","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12964-020-00544-7","volume":"18","author":"M Mota","year":"2020","unstructured":"Mota M, Shevde LA (2020) Merlin regulates signaling events at the nexus of development and cancer. Cell Commun Signal 18(1):63","journal-title":"Cell Commun Signal"},{"issue":"13","key":"4995_CR33","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202400019RR","volume":"38","author":"R Vlashi","year":"2024","unstructured":"Vlashi R, Sun F, Zheng C, Zhang X, Liu J, Chen G (2024) The molecular biology of NF2\/Merlin on tumorigenesis and development. FASEB J 38(13):e23809","journal-title":"FASEB J"},{"key":"4995_CR34","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1101\/gad.14.13.1617","volume":"14","author":"M Giovannini","year":"2000","unstructured":"Giovannini M, Robanus-Maandag E, van der Valk M, Niwa-Kawakita M, Abramowski V, Goutebroze L, Woodruff JM, Berns A, Thomas G (2000) Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2. Genes Dev 14:1617\u20131630","journal-title":"Genes Dev"},{"issue":"8","key":"4995_CR35","doi-asserted-by":"publisher","first-page":"299","DOI":"10.2176\/jns-nmc.2024-0067","volume":"64","author":"R Tamura","year":"2024","unstructured":"Tamura R, Yo M, Toda M (2024) Historical development of diagnostic criteria for NF2-related schwannomatosis. Neurol Med Chir (Tokyo) 64(8):299\u2013308","journal-title":"Neurol Med Chir (Tokyo)"},{"key":"4995_CR36","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1038\/s41467-017-00346-5","volume":"8","author":"J Vitte","year":"2017","unstructured":"Vitte J, Gao F, Coppola G, Judkins AR, Giovannini M (2017) Timing of Smarcb1 and Nf2 inactivation determines schwannoma versus rhabdoid tumor development. Nat Commun 8:300","journal-title":"Nat Commun"},{"issue":"11","key":"4995_CR37","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.1007\/s13346-023-01370-3","volume":"13","author":"S Najafi","year":"2023","unstructured":"Najafi S, Majidpoor J, Mortezaee K (2023) Extracellular vesicle-based drug delivery in cancer immunotherapy. Drug Deliv Transl Res 13(11):2790\u20132806","journal-title":"Drug Deliv Transl Res"},{"issue":"1","key":"4995_CR38","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s42003-022-03021-8","volume":"5","author":"T Haraguchi","year":"2022","unstructured":"Haraguchi T, Koujin T, Shindo T, Bilir \u015e, Osakada H, Nishimura K, Hirano Y, Asakawa H, Mori C, Kobayashi S, Okada Y, Chikashige Y, Fukagawa T, Shibata S, Hiraoka Y (2022) Transfected plasmid DNA is incorporated into the nucleus via nuclear envelope reformation at telophase. Commun Biol 5(1):78","journal-title":"Commun Biol"},{"issue":"1","key":"4995_CR39","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41392-021-00487-6","volume":"6","author":"JT Bulcha","year":"2021","unstructured":"Bulcha JT, Wang Y, Ma H, Tai PWL, Gao G (2021) Viral vector platforms within the gene therapy landscape. Signal Transduct Target Ther 6(1):53","journal-title":"Signal Transduct Target Ther"},{"key":"4995_CR40","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41392-024-01780-w","volume":"9","author":"JH Wang","year":"2024","unstructured":"Wang JH, Gessler DJ, Zhan W, Gallagher TL, Gao G (2024) Adeno-associated virus as a delivery vector for gene therapy of human diseases. Signal Transduct Target Ther 9:78","journal-title":"Signal Transduct Target Ther"},{"issue":"7","key":"4995_CR41","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1089\/hum.2016.087","volume":"27","author":"M Hocquemiller","year":"2016","unstructured":"Hocquemiller M, Giersch L, Audrain M, Parker S, Cartier N (2016) Adeno-associated virus-based gene therapy for CNS diseases. Hum Gene Ther 27(7):478\u2013496","journal-title":"Hum Gene Ther"},{"issue":"2","key":"4995_CR42","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.ymthe.2019.11.012","volume":"28","author":"T Taghian","year":"2020","unstructured":"Taghian T, Marosfoi MG, Puri AS, Cataltepe OI, King RM, Diffie EB, Maguire AS, Martin DR, Fernau D, Batista AR, Kuchel T, Christou C, Perumal R, Chandra S, Gamlin PD, Bertrand SG, Flotte TR, McKenna-Yasek D, Tai PWL, Aronin N, Gounis MJ, Sena-Esteves M, Gray-Edwards HL (2020) A safe and reliable technique for CNS delivery of AAV vectors in the Cisterna Magna. Mol Ther 28(2):411\u2013421","journal-title":"Mol Ther"},{"key":"4995_CR43","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.omtm.2020.04.001","volume":"17","author":"K Bey","year":"2020","unstructured":"Bey K, Deniaud J, Dubreil L, Joussemet B, Cristini J, Ciron C, Hordeaux J, Le Boulc\u2019h M, Marche K, Maquigneau M, Guilbaud M, Moreau R, Larcher T, Deschamps JY, Fusellier M, Blouin V, Sevin C, Cartier N, Adjali O, Aubourg P, Moullier P, Colle MA (2020) Intra-CSF AAV9 and AAVrh10 administration in nonhuman primates: promising routes and vectors for which neurological diseases? Mol Ther Methods Clin Dev 17:771\u2013784","journal-title":"Mol Ther Methods Clin Dev"},{"key":"4995_CR44","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/onc.2015.125","volume":"35","author":"AM Petrilli","year":"2016","unstructured":"Petrilli AM, Fernandez-Valle C (2016) Role of Merlin\/NF2 inactivation in tumor biology. Oncogene 35:537\u2013548","journal-title":"Oncogene"},{"issue":"1","key":"4995_CR45","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s12935-023-02940-8","volume":"23","author":"MA Ghalavand","year":"2023","unstructured":"Ghalavand MA, Asghari A, Farhadi M, Taghizadeh-Hesary F, Garshasbi M, Falah M (2023) The genetic landscape and possible therapeutics of neurofibromatosis type 2. Cancer Cell Int 23(1):99","journal-title":"Cancer Cell Int"},{"issue":"1","key":"4995_CR46","doi-asserted-by":"publisher","first-page":"9543","DOI":"10.1038\/s41598-022-13580-9","volume":"12","author":"Y Teranishi","year":"2022","unstructured":"Teranishi Y, Miyawaki S, Nakatomi H, Ohara K, Hongo H, Dofuku S, Okano A, Takayanagi S, Ota T, Yoshimura J, Qu W, Mitsui J, Morishita S, Tsuji S, Saito N (2022) Early prediction of functional prognosis in neurofibromatosis type 2 patients based on genotype-phenotype correlation with targeted deep sequencing. Sci Rep 12(1):9543","journal-title":"Sci Rep"},{"issue":"4","key":"4995_CR47","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/j.gendis.2022.02.007","volume":"10","author":"U Anand","year":"2022","unstructured":"Anand U, Dey A, Chandel AKS, Sanyal R, Mishra A, Pandey DK, De Falco V, Upadhyay A, Kandimalla R, Chaudhary A, Dhanjal JK, Dewanjee S, Vallamkondu J, P\u00e9rez de la Lastra JM (2022) Cancer chemotherapy and beyond: current status, drug candidates, associated risks and progress in targeted therapeutics. Genes Dis 10(4):1367\u20131401","journal-title":"Genes Dis"},{"key":"4995_CR48","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/cgt.2009.71","volume":"17","author":"S Prabhakar","year":"2010","unstructured":"Prabhakar S, Brenner GJ, Sung B, Messerli SM, Mao J, Sena-Esteves M, Stemmer-Rachamimov A, Tannous B, Breakefield XO (2010) Imaging and therapy of experimental schwannomas using HSV amplicon vector-encoding apoptotic protein under Schwann cell promoter. Cancer Gene Ther 17:266\u2013274","journal-title":"Cancer Gene Ther"},{"key":"4995_CR49","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1089\/hum.2012.094","volume":"24","author":"S Prabhakar","year":"2013","unstructured":"Prabhakar S, Taherian M, Gianni D, Conlon TJ, Fulci G, Brockmann J, Stemmer-Rachamimov A, Sena-Esteves M, Breakefield XO, Brenner GJ (2013) Regression of schwannomas induced by adeno-associated virus-mediated delivery of caspase-1. Hum Gene Ther 24:152\u2013162","journal-title":"Hum Gene Ther"},{"key":"4995_CR50","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1093\/neuonc\/noz065","volume":"21","author":"SG Ahmed","year":"2019","unstructured":"Ahmed SG, Abdelnabi A, Maguire CA, Doha M, Sagers JE, Lewis RM, Muzikansky A, Giovannini M, Stemmer-Rachamimov A, Stankovic KM, Fulci G, Brenner GJ (2019) Gene therapy with apoptosis-associated speck-like protein, a newly described schwannoma tumor suppressor, inhibits schwannoma growth in vivo. Neuro Oncol 21:854\u2013866","journal-title":"Neuro Oncol"},{"key":"4995_CR51","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/s41417-018-0077-3","volume":"26","author":"SG Ahmed","year":"2019","unstructured":"Ahmed SG, Abdelanabi A, Doha M, Brenner GJ (2019) Schwannoma gene therapy by adeno-associated virus delivery of the pore-forming protein Gasdermin-D. Cancer Gene Ther 26:259\u2013267","journal-title":"Cancer Gene Ther"},{"key":"4995_CR52","doi-asserted-by":"publisher","first-page":"819","DOI":"10.3390\/ijms23020819","volume":"23","author":"SG Ahmed","year":"2022","unstructured":"Ahmed SG, Maguire CA, Cao SA, Brenner GJ (2022) Schwannoma gene therapy via adeno-associated viral vector delivery of apoptosis-associated speck-like protein containing CARD (ASC): preclinical efficacy and safety. Int J Mol Sci 23:819","journal-title":"Int J Mol Sci"},{"key":"4995_CR53","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s10571-015-0309-0","volume":"36","author":"J Hall","year":"2016","unstructured":"Hall J, Prabhakar S, Balaj L, Lai CP, Cerione RA, Breakefield XO (2016) Delivery of therapeutic proteins via extracellular vesicles, review and potential treatments for Parkinson\u2019s disease, glioma and schwannoma. Cell Mol Neurobiol 36:417\u2013427","journal-title":"Cell Mol Neurobiol"},{"key":"4995_CR54","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/mt.2012.161","volume":"21","author":"A Mizrak","year":"2013","unstructured":"Mizrak A, Bolukbasi MF, Ozdener GB, Brenner GJ, Madlener S, Erkan EP, Str\u00f6bel T, Breakefield XO, Saydam O (2013) Genetically engineered microvesicles carrying suicide mRNA\/protein inhibit schwannoma tumor growth. Mol Ther 21:101\u2013108","journal-title":"Mol Ther"},{"issue":"1","key":"4995_CR55","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s12964-023-01103-6","volume":"21","author":"YJ Liu","year":"2023","unstructured":"Liu YJ, Wang C (2023) A review of the regulatory mechanisms of extracellular vesicles-mediated intercellular communication. Cell Commun Signal 21(1):77","journal-title":"Cell Commun Signal"},{"issue":"1","key":"4995_CR56","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41392-024-01735-1","volume":"9","author":"MA Kumar","year":"2024","unstructured":"Kumar MA, Baba SK, Sadida HQ, Marzooqi SA, Jerobin J, Altemani FH, Algehainy N, Alanazi MA, Abou-Samra AB, Kumar R, Al-Shabeeb Akil AS, Macha MA, Mir R, Bhat AA (2024) Extracellular vesicles as tools and targets in therapy for diseases. Signal Transduct Target Ther 9(1):27","journal-title":"Signal Transduct Target Ther"},{"issue":"5","key":"4995_CR57","doi-asserted-by":"publisher","DOI":"10.1002\/jev2.12433","volume":"13","author":"C Fusco","year":"2024","unstructured":"Fusco C, De Rosa G, Spatocco I, Vitiello E, Procaccini C, Frig\u00e8 C, Pellegrini V, La Grotta R, Furlan R, Matarese G, Prattichizzo F, de Candia P (2024) Extracellular vesicles as human therapeutics: a scoping review of the literature. J Extracell Vesicles 13(5):e12433","journal-title":"J Extracell Vesicles"},{"issue":"1","key":"4995_CR58","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41392-023-01366-y","volume":"8","author":"JW Bai","year":"2023","unstructured":"Bai JW, Qiu SQ, Zhang GJ (2023) Molecular and functional imaging in cancer-targeted therapy: current applications and future directions. Signal Transduct Target Ther 8(1):89","journal-title":"Signal Transduct Target Ther"},{"key":"4995_CR59","doi-asserted-by":"publisher","first-page":"6191","DOI":"10.1158\/0008-5472.CAN-11-4079","volume":"72","author":"AR Carson","year":"2012","unstructured":"Carson AR, McTiernan CF, Lavery L, Grata M, Leng X, Wang J, Chen X, Villanueva FS (2012) Ultrasound-targeted microbubble destruction to deliver siRNA cancer therapy. Cancer Res 72:6191\u20136199","journal-title":"Cancer Res"},{"key":"4995_CR60","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1056\/NEJMoa2021712","volume":"384","author":"SF Garrelfs","year":"2021","unstructured":"Garrelfs SF, Frishberg Y, Hulton SA, Koren MJ, O\u2019Riordan WD, Cochat P, Desch\u00eanes G, Shasha-Lavsky H, Saland JM, Van\u2019t Hoff WG, Fuster DG, Magen D, Moochhala SH, Schalk G, Simkova E, Groothoff JW, Sas DJ, Meliambro KA, Lu J, Sweetser MT, Garg PP, Vaishnaw AK, Gansner JM, McGregor TL, Lieske JC,  ILLUMINATE-A Collaborators (2021) Lumasiran, an RNAi therapeutic for primary hyperoxaluria type 1. N Engl J Med 384:1216\u20131226","journal-title":"N Engl J Med"},{"key":"4995_CR61","doi-asserted-by":"publisher","first-page":"R53","DOI":"10.1093\/hmg\/ddv442","volume":"25","author":"MS Keiser","year":"2016","unstructured":"Keiser MS, Kordasiewicz HB, McBride JL (2016) Gene suppression strategies for dominantly inherited neurodegenerative diseases, lessons from Huntington\u2019s disease and spinocerebellar ataxia. Hum Mol Genet 25:R53-64","journal-title":"Hum Mol Genet"},{"key":"4995_CR62","doi-asserted-by":"publisher","first-page":"7138","DOI":"10.1016\/j.biomaterials.2012.06.068","volume":"33","author":"P Kesharwani","year":"2012","unstructured":"Kesharwani P, Gajbhiye V, Jain NK (2012) A review of nanocarriers for the delivery of small interfering RNA. Biomaterials 33:7138\u20137150","journal-title":"Biomaterials"},{"key":"4995_CR63","doi-asserted-by":"publisher","first-page":"5469","DOI":"10.1158\/1078-0432.CCR-10-1994","volume":"16","author":"A Santel","year":"2010","unstructured":"Santel A, Aleku M, R\u00f6der N, M\u00f6pert K, Durieux B, Janke O, Keil O, Endruschat J, Dames S, Lange C, Eisermann M, L\u00f6ffler K, Fechtner M, Fisch G, Vank C, Schaeper U, Giese K, Kaufmann J (2010) Atu027 prevents pulmonary metastasis in experimental and spontaneous mouse metastasis models. Clin Cancer Res 16:5469\u20135480","journal-title":"Clin Cancer Res"},{"key":"4995_CR64","doi-asserted-by":"publisher","first-page":"76","DOI":"10.5414\/CPP50076","volume":"50","author":"D Strumberg","year":"2012","unstructured":"Strumberg D, Schultheis B, Traugott U, Vank C, Santel A, Keil O, Giese K, Kaufmann J, Drevs J (2012) Phase I clinical development of Atu027, a siRNA formulation targeting PKN3 in patients with advanced solid tumors. Int J Clin Pharmacol Ther 50:76\u201378","journal-title":"Int J Clin Pharmacol Ther"},{"key":"4995_CR65","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.omtm.2022.06.012","volume":"26","author":"S Prabhakar","year":"2022","unstructured":"Prabhakar S, Beauchamp RL, Cheah PS, Yoshinaga A, Haidar EA, Lule S, Mani G, Maalouf K, Stemmer-Rachamimov A, Jung DH, Welling DB, Giovannini M, Plotkin SR, Maguire CA, Ramesh V, Breakefield XO (2022) Gene replacement therapy in a schwannoma mouse model of neurofibromatosis type 2. Mol Ther Methods Clin Dev 26:169\u2013180","journal-title":"Mol Ther Methods Clin Dev"},{"key":"4995_CR66","doi-asserted-by":"crossref","unstructured":"Hexter A, Jones A, Joe H, Heap L, Smith MJ, Wallace AJ, Halliday D, Parry A, Taylor A, Raymond L, Shaw A, Afridi S, Obholzer R, Axon P, King AT, English Specialist NF2 Research Group, Friedman JM, Evans DG (2015) Clinical and molecular predictors of mortality in neurofibromatosis 2: a UK national analysis of 1192 patients. J Med Genet 52:699\u2013705.","DOI":"10.1136\/jmedgenet-2015-103290"},{"key":"4995_CR67","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/ejhg.2012.261","volume":"21","author":"E Castellanos","year":"2013","unstructured":"Castellanos E, Rosas I, Solanes A, Bielsa I, L\u00e1zaro C, Carrato C, Hostalot C, Prades P, Roca-Ribas F, Blanco I, Serra E (2013) NF2 Multidisciplinary Clinics HUGTiP-ICO-IMPPC. In vitro antisense therapeutics for a deep intronic mutation causing Neurofibromatosis type 2. Eur J Hum Genet 21:769\u2013773","journal-title":"Eur J Hum Genet"},{"key":"4995_CR68","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.omtn.2022.10.026","volume":"30","author":"N Catas\u00fas","year":"2022","unstructured":"Catas\u00fas N, Rosas I, Bonache S, Negro A, Torres-Martin M, Plana-Pla A, Salvador H, Serra E, Blanco I, Castellanos E (2022) Antisense oligonucleotides targeting exon 11 are able to partially rescuethe Neurofibromatosis Type 2 phenotype in vitro. Mol Ther Nucleic Acids 30:493\u2013505","journal-title":"Mol Ther Nucleic Acids"},{"key":"4995_CR69","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1126\/science.1231143","volume":"339","author":"L Cong","year":"2013","unstructured":"Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, Hsu PD, Wu X, Jiang W, Marraffini LA, Zhang F (2013) Multiplex genome engineering using CRISPR\/Cas systems. Science 339:819\u2013823","journal-title":"Science"},{"key":"4995_CR70","doi-asserted-by":"publisher","first-page":"483","DOI":"10.2176\/nmc.ra.2020-0049","volume":"60","author":"R Tamura","year":"2020","unstructured":"Tamura R, Toda M (2020) Historic overview of genetic engineering technologies for human gene therapy. Neurol Med Chir (Tokyo) 60:483\u2013491","journal-title":"Neurol Med Chir (Tokyo)"},{"key":"4995_CR71","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/j.cell.2016.04.003","volume":"165","author":"T Yamano","year":"2016","unstructured":"Yamano T, Nishimasu H, Zetsche B, Hirano H, Slaymaker IM, Li Y, Fedorova I, Nakane T, Makarova KS, Koonin EV, Ishitani R, Zhang F, Nureki O (2016) Crystal structure of Cpf1 in complex with guide RNA and target DNA. Cell 165:949\u2013962","journal-title":"Cell"},{"key":"4995_CR72","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/bs.pbr.2016.11.003","volume":"230","author":"G Gowing","year":"2017","unstructured":"Gowing G, Svendsen S, Svendsen CN (2017) Ex vivo gene therapy for the treatment of neurological disorders. Prog Brain Res 230:99\u2013132","journal-title":"Prog Brain Res"},{"key":"4995_CR73","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.ymthe.2020.12.007","volume":"29","author":"JR Mendell","year":"2021","unstructured":"Mendell JR, Al-Zaidy SA, Rodino-Klapac LR, Goodspeed K, Gray SJ, Kay CN, Boye SL, Boye SE, George LA, Salabarria S, Corti M, Byrne BJ, Tremblay JP (2021) Current clinical applications of in vivo gene therapy with AAVs. Mol Ther 29:464\u2013488","journal-title":"Mol Ther"},{"key":"4995_CR74","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.cell.2024.01.042","volume":"187","author":"M Pacesa","year":"2024","unstructured":"Pacesa M, Pelea O, Jinek M (2024) Past, present, and future of CRISPR genome editing technologies. Cell 187:1076\u20131100","journal-title":"Cell"},{"key":"4995_CR75","doi-asserted-by":"publisher","unstructured":"Murray JB, Harrison PT, Scholefield J (2024) Prime editing: therapeutic advances and mechanistic insights. Gene Ther. https:\/\/doi.org\/10.1038\/s41434-024-00499-1","DOI":"10.1038\/s41434-024-00499-1"},{"key":"4995_CR76","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41551-024-01227-1","volume":"9","author":"S Pandey","year":"2025","unstructured":"Pandey S, Gao XD, Krasnow NA, McElroy A, Tao YA, Duby JE, Steinbeck BJ, McCreary J, Pierce SE, Tolar J, Meissner TB, Chaikof EL, Osborn MJ, Liu DR (2025) Efficient site-specific integration of large genes in mammalian cells via continuously evolved recombinases and prime editing. Nat Biomed Eng 9:22\u201339","journal-title":"Nat Biomed Eng"},{"key":"4995_CR77","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1159\/000442514","volume":"21","author":"SK Plontke","year":"2016","unstructured":"Plontke SK, Hartsock JJ, Gill RM, Salt AN (2016) Intracochlear drug injections through the round window membrane: measures to improve drug retention. Audiol Neurotol 21:72\u201379","journal-title":"Audiol Neurotol"},{"key":"4995_CR78","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1038\/nbt.3801","volume":"35","author":"B Pan","year":"2017","unstructured":"Pan B, Askew C, Galvin A, Heman-Ackah S, Asai Y, Indzhykulian AA, Jodelka FM, Hastings ML, Lentz JJ, Vandenberghe LH, Holt JR, G\u00e9l\u00e9oc GS (2017) Gene therapy restores auditory and vestibular function in a mouse model of Usher syndrome type 1c. Nat Biotechnol 35:264\u2013272","journal-title":"Nat Biotechnol"},{"key":"4995_CR79","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201809396","volume":"11","author":"H Al-Moyed","year":"2019","unstructured":"Al-Moyed H, Cepeda AP, Jung S, Moser T, K\u00fcgler S, Reisinger E (2019) A dual-AAV approach restores fast exocytosis and partially rescues auditory function in deaf otoferlin knock-out mice. EMBO Mol Med 11:e9396","journal-title":"EMBO Mol Med"},{"key":"4995_CR80","doi-asserted-by":"publisher","first-page":"4496","DOI":"10.1073\/pnas.1817537116","volume":"116","author":"O Akil","year":"2019","unstructured":"Akil O, Dyka F, Calvet C, Emptoz A, Lahlou G, Nouaille S, Boutet de Monvel J, Hardelin JP, Hauswirth WW, Avan P, Petit C, Safieddine S, Lustig LR (2019) Dual AAVmediated gene therapy restores hearing in a DFNB9 mouse model. Proc Natl Acad Sci USA 116:4496\u20134501","journal-title":"Proc Natl Acad Sci USA"},{"key":"4995_CR81","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/nbt.3081","volume":"33","author":"JA Zuris","year":"2015","unstructured":"Zuris JA, Thompson DB, Shu Y, Guilinger JP, Bessen JL, Hu JH, Maeder ML, Joung JK, Chen ZY, Liu DR (2015) Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo. Nat Biotechnol 33:73\u201380","journal-title":"Nat Biotechnol"},{"key":"4995_CR82","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nature25164","volume":"553","author":"X Gao","year":"2018","unstructured":"Gao X, Tao Y, Lamas V, Huang M, Yeh WH, Pan B, Hu YJ, Hu JH, Thompson DB, Shu Y, Li Y, Wang H, Yang S, Xu Q, Polley DB, Liberman MC, Kong WJ, Holt JR, Chen ZY, Liu DR (2018) Treatment of autosomal dominant hearing loss by in vivo delivery of genome editing agents. Nature 553:217\u2013221","journal-title":"Nature"},{"key":"4995_CR83","doi-asserted-by":"publisher","first-page":"323","DOI":"10.3389\/fncel.2019.00323","volume":"13","author":"Y Ren","year":"2019","unstructured":"Ren Y, Landegger LD, Stankovic KM (2019) Gene therapy for human sensorineural hearing loss. Front Cell Neurosci 13:323","journal-title":"Front Cell Neurosci"},{"key":"4995_CR84","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1016\/j.ymthe.2023.10.015","volume":"31","author":"D Duan","year":"2023","unstructured":"Duan D (2023) Lethal immunotoxicity in high-dose systemic AAV therapy. Mol Ther 31:3123\u20133126","journal-title":"Mol Ther"},{"key":"4995_CR85","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1056\/NEJMoa2307798","volume":"389","author":"A Lek","year":"2023","unstructured":"Lek A, Wong B, Keeler A, Blackwood M, Ma K, Huang S, Sylvia K, Batista AR, Artinian R, Kokoski D, Parajuli S, Putra J, Carreon CK, Lidov H, Woodman K, Pajusalu S, Spinazzola JM, Gallagher T, LaRovere J, Balderson D, Black L, Sutton K, Horgan R, Lek M, Flotte T (2023) Death after high-dose rAAV9 gene therapy in a patient with Duchenne\u2019s muscular dystrophy. N Engl J Med 389:1203\u20131210","journal-title":"N Engl J Med"},{"key":"4995_CR86","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1161\/CIRCULATIONAHA.122.063759","volume":"148","author":"X Li","year":"2023","unstructured":"Li X, La Salvia S, Liang Y, Adamiak M, Kohlbrenner E, Jeong D, Chepurko E, Ceholski D, Lopez-Gordo E, Yoon S, Mathiyalagan P, Agarwal N, Jha D, Lodha S, Daaboul G, Phan A, Raisinghani N, Zhang S, Zangi L, Gonzalez-Kozlova E, Dubois N, Dogra N, Hajjar RJ, Sahoo S (2023) Extracellular vesicle-encapsulated adeno-associated viruses for therapeutic gene delivery to the heart. Circulation 148:405\u2013425","journal-title":"Circulation"},{"key":"4995_CR87","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1002\/bit.28482","volume":"120","author":"S Takatsuka","year":"2023","unstructured":"Takatsuka S, Kubota T, Kurashina Y, Kurihara S, Hirabayashi M, Fujioka M, Okano HJ, Onoe H (2023) Controlled release of adeno-associated virus from alginate hydrogel microbeads with enhanced sensitivity to ultrasound. Biotechnol Bioeng 120:2371\u20132377","journal-title":"Biotechnol Bioeng"},{"key":"4995_CR88","doi-asserted-by":"crossref","unstructured":"Gan C, Leng M, Liu Y, Zheng Z, He S, Qiao W, Xiao L, Xiao Y, Ye J, Zhou L, Zhou J, Xiao B, Zhao W, Yang J, Wu A, Zhang H, Hu H, Cen X, Qian Z, Dong H, Valencia CA, Dai L, Chow HY, Zhang L, Dong B (2024) The combination of rAAV pseudo-lipid nanoparticle and triamcinolone acetonide enables multi-administration to liver. Mol Ther Methods Clin Dev 33(1):101399","DOI":"10.1016\/j.omtm.2024.101399"},{"key":"4995_CR89","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1089\/hum.2022.138","volume":"33","author":"S Prasad","year":"2022","unstructured":"Prasad S, Dimmock DP, Greenberg B, Walia JS, Sadhu C, Tavakkoli F, Lipshutz GS (2022) Immune responses and immunosuppressive strategies for adeno-associated virus-based gene therapy for treatment of central nervous system disorders: current knowledge and approaches. Hum Gene Ther 33:1228\u20131245","journal-title":"Hum Gene Ther"},{"key":"4995_CR90","doi-asserted-by":"publisher","first-page":"3220","DOI":"10.1016\/j.ymthe.2024.07.016","volume":"32","author":"B Vrellaku","year":"2024","unstructured":"Vrellaku B, Sethw Hassan I, Howitt R, Webster CP, Harriss E, McBlane F, Betts C, Schettini J, Lion M, Mindur JE, Duerr M, Shaw PJ, Kirby J, Azzouz M, Servais L (2024) A systematic review of immunosuppressive protocols used in AAV gene therapy for monogenic disorders. Mol Ther 32:3220\u20133259","journal-title":"Mol Ther"},{"issue":"1","key":"4995_CR91","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jneumeth.2010.10.021","volume":"195","author":"O Saydam","year":"2011","unstructured":"Saydam O, Ozdener GB, Senol O, Mizrak A, Prabhakar S, Stemmer-Rachamimov AO, Breakefield XO, Brenner GJ (2011) A novel imaging-compatible sciatic nerve schwannoma model. J Neurosci Methods 195(1):75\u201377","journal-title":"J Neurosci Methods"},{"issue":"2","key":"4995_CR92","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41596-018-0105-7","volume":"14","author":"J Chen","year":"2019","unstructured":"Chen J, Landegger LD, Sun Y, Ren J, Maimon N, Wu L, Ng MR, Chen JW, Zhang N, Zhao Y, Gao X, Fujita T, Roberge S, Huang P, Jain RK, Plotkin SR, Stankovic KM, Xu L (2019) A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma. Nat Protoc 14(2):541\u2013555","journal-title":"Nat Protoc"},{"issue":"1","key":"4995_CR93","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/hmg\/ddu414","volume":"24","author":"JR Gehlhausen","year":"2015","unstructured":"Gehlhausen JR, Park SJ, Hickox AE, Shew M, Staser K, Rhodes SD, Menon K, Lajiness JD, Mwanthi M, Yang X, Yuan J, Territo P, Hutchins G, Nalepa G, Yang FC, Conway SJ, Heinz MG, Stemmer-Rachamimov A, Yates CW, Wade CD (2015) A murine model of neurofibromatosis type 2 that accurately phenocopies human schwannoma formation. Hum Mol Genet 24(1):1\u20138","journal-title":"Hum Mol Genet"},{"key":"4995_CR94","doi-asserted-by":"publisher","first-page":"531","DOI":"10.2174\/1566523215666150929110424","volume":"15","author":"C Gopinath","year":"2015","unstructured":"Gopinath C, Nathar TJ, Ghosh A, Hickstein DD, Nelson EJR (2015) Contemporary animal models for human gene therapy applications. Curr Gene Ther 15:531\u2013540","journal-title":"Curr Gene Ther"},{"key":"4995_CR95","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s42003-018-0163-y","volume":"1","author":"SH Isakson","year":"2018","unstructured":"Isakson SH, Rizzardi AE, Coutts AW, Carlson DF, Kirstein MN, Fisher J, Vitte J, Williams KB, Pluhar GE, Dahiya S, Widemann BC, Dombi E, Rizvi T, Ratner N, Messiaen L, Stemmer-Rachamimov AO, Fahrenkrug SC, Gutmann DH, Giovannini M, Moertel CL, Largaespada DA, Watson AL (2018) Genetically engineered minipigs model the major clinical features of human neurofibromatosis type 1. Commun Biol 1:158","journal-title":"Commun Biol"},{"key":"4995_CR96","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.120402","volume":"3","author":"KA White","year":"2018","unstructured":"White KA, Swier VJ, Cain JT, Kohlmeyer JL, Meyerholz DK, Tanas MR, Uthoff J, Hammond E, Li H, Rohret FA, Goeken A, Chan CH, Leidinger MR, Umesalma S, Wallace MR, Dodd RD, Panzer K, Tang AH, Darbro BW, Moutal A, Cai S, Li W, Bellampalli SS, Khanna R, Rogers CS, Sieren JC, Quelle DE, Weimer JM (2018) A porcine model of neurofibromatosis type 1 that mimics the human disease. JCI Insight 3:e120402","journal-title":"JCI Insight"},{"issue":"3","key":"4995_CR97","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/s41576-022-00541-1","volume":"24","author":"PJ Chen","year":"2023","unstructured":"Chen PJ, Liu DR (2023) Prime editing for precise and highly versatile genome manipulation. Nat Rev Genet 24(3):161\u2013177","journal-title":"Nat Rev Genet"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-04995-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-025-04995-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-04995-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T10:02:43Z","timestamp":1748253763000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-025-04995-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,7]]},"references-count":97,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["4995"],"URL":"https:\/\/doi.org\/10.1007\/s11060-025-04995-1","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,7]]},"assertion":[{"value":"11 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethical approval is not required for this review article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"This review article does not include information that may identify the person.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}